Table 2.
IDH1 SNP+ (n = 21) |
IDH1 SNP− (n = 165) |
|||
---|---|---|---|---|
N | % | N | % | |
Favorable risk | ||||
CBF AML | 0 | 0 | 20 | 12 |
CN, FLT3− | 1 | 5 | 41 | 25 |
Adverse risk | ||||
CN, FLT3+ | 9 | 43 | 29 | 18 |
Any other cytogenetics | 11 | 52 | 75 | 45 |
IDH1 SNP+ (n = 21) |
IDH1 SNP− (n = 165) |
|||
---|---|---|---|---|
N | % | N | % | |
Favorable risk | ||||
CBF AML | 0 | 0 | 20 | 12 |
CN, FLT3− | 1 | 5 | 41 | 25 |
Adverse risk | ||||
CN, FLT3+ | 9 | 43 | 29 | 18 |
Any other cytogenetics | 11 | 52 | 75 | 45 |